Kyle Concannon, MD

Physician-scientist in lung cancer l University of Colorado l MD Anderson trained l Cracking Cancer Host l Native Vermonter.

[Cracking Cancer Podcast @Cracking_Cancer]

The INTerpath 009 clinical trial is testing a revolutionary mRNA vaccine on stage 2 and 3, non-small cell lung cancer patients.

Share with your friends and family, and find more information through the number below!
720-848-9264

[Cracking Cancer Podcast @Cracking_Cancer]

A past study linked coffee to lung cancer, but missed a huge detail: coffee drinkers simply smoked more. Association doesn't equal causation.

Support ➡️ https://t.co/JINFHb8KGy

https://t.co/kJRqeUCGF1

[Rob Swanda @ScientistSwanda]

Xeloda is a powerful oral chemo that helps to destroy tumors from within at any cell stage, giving it a unique edge. It works by disrupting DNA synthesis so cancer cells can’t keep dividing. Learn about the science of Xeloda in my latest video!
https://t.co/LnkYwkngP0

[Kyle Concannon, MD @kyleconcannonMD]

A great series about her2 driven lung cancer! Thank you all for inviting me on!

[Young Lung Cancer Initiative @YoungLungCancer]

New 3-part series on HER2-driven lung cancer with thoracic oncologist Dr. @kyleconcannonMD
What it is, how it's treated, and what happens when treatment stops working.

Watch: https://t.co/7hDwFOcjgD

Thank you to Boehringer Ingelheim for making this series possible.

[Cracking Cancer Podcast @Cracking_Cancer]

This week we are highlighting the Summit 112-3007 trial, an exciting study investigating a cancer protein binding antibody.

To inquire for more information, please call 720-848-9264

[Rob Swanda @ScientistSwanda]

Ferroptosis is an iron‑dependent form of cell death that’s gaining major attention in cancer. By triggering oxidative damage in tumor cells, it may open new doors for therapies. Explore this cutting‑edge concept in my new explainer video!
https://t.co/gxGu6dgNOz

[Cracking Cancer Podcast @Cracking_Cancer]

This week we are highlighting the AbbVie 25-287 trial involving TMAB-A. This is an exciting study looking deeper into the MET resistance pathway of EGFR mutated cancers. Give it a look, or tell your friends!

[Cracking Cancer Podcast @Cracking_Cancer]

The depth of knowledge around cancer is frighteningly deep. You’re not alone if you feel lost in it all. Learn small pieces at a time, and you’ll start feeling empowered.

Support ➡️ https://t.co/JINFHb8KGy

https://t.co/LIqogVW6BB

[Kyle Concannon, MD @kyleconcannonMD]

As a new physician scientist working on cellular therapies, it’s hard to not be frustrated at the slow pace and high cost of getting things into clinic here. Hopefully we can learn what they’re doing well and adapt quickly. The US hemorrhaged PIs to pharma, soon it may be to China.

[Cracking Cancer Podcast @Cracking_Cancer]

Oncologists love when patients do their own research. Cancer steals control, but understanding your body brings it back.

Support ➡️ https://t.co/JINFHb8KGy

https://t.co/LIqogVW6BB

[Kyle Concannon, MD @kyleconcannonMD]

@GIMedOnc @PTarantinoMD China is blowing us out of the water with early phase innovation in my opinion. Great for their population - but we need to lower our barriers to trial entry with these things promising assets.

[Young Lung Cancer Initiative @YoungLungCancer]

There are three types of HER2 alterations in lung cancer, and which type a patient has could change the treatment strategy. Dr @kyleconcannonMD breaks it down.

Full Her2 Series Here: https://t.co/Jt0xoO7URg

Thanks to Boehringer Ingelheim for sponsoring this series

[Cracking Cancer Podcast @Cracking_Cancer]

We talk a lot about how long someone will live, but quality of life matters just as much. Clarity reduces the fear and uncertainty of cancer care.

Support ➡️ https://t.co/JINFHb8KGy

https://t.co/LIqogVW6BB

[Kyle Concannon, MD @kyleconcannonMD]

@YoungLungCancer @ALKPositiveinc @ALKpositiveINT @OncogeneCancer @CUCancerCenter

[Cracking Cancer Podcast @Cracking_Cancer]

Dr. Rob Swanda amazingly describes what is going on in the TRIANA ALK trial!

#TRIANA #alktrial #cancer

[Rob Swanda @ScientistSwanda]

details on the trial can be found here!

[Young Lung Cancer Initiative @YoungLungCancer]

Thank you for having us & @kyleconcannonMD ! 🤍

[Kyle Concannon, MD @kyleconcannonMD]

Trial watch at Colorado thoracic @KRASKickers @YoungLungCancer @TheWRP4LC

[Cracking Cancer Podcast @Cracking_Cancer]

The Cracking Cancer Podcast is happy to announce a new series, where we highlight ongoing cancer trials of interest. Check them out every week!

[Rob Swanda @ScientistSwanda]

Tremfya is a breakthrough biologic that targets inflammation at its source. By blocking the IL‑23 pathway, it helps calm overactive immune responses seen in conditions like psoriasis. I put together a quick video that shows how this targeted therapy works!
https://t.co/3KcCdHLNiT

[Cracking Cancer Podcast @Cracking_Cancer]

It's not a magic pill. It actually acts like a standard chemo, but it's less safe and less effective than the treatments we already use.

Support ➡️ https://t.co/JINFHb8KGy

https://t.co/03tzTdVE3K

[Rob Swanda @ScientistSwanda]

Back on the @Cracking_Cancer podcast for round two! Appreciated the chance to re-join @kyleconcannonMD and patient advocate Samantha to dive into the misconceptions around fenbendazole as a cancer treatment.
Hope you enjoy the listen (link in comments)! 😊